title: Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure.
abstract: BACKGROUND
  Previous work has failed to demonstrate reduced maximal contraction of isolated ventricular myocytes from failing human hearts compared with nonfailing control hearts. The effect of alterations in stimulation frequency and temperature on the contraction of isolated ventricular myocytes has been investigated. Left ventricular myocytes were isolated from the hearts of patients with severe heart failure undergoing heart transplantation and compared with myocytes isolated from myocardial biopsies from patients with coronary disease but preserved left ventricular systolic function or from myocytes from rejected donor hearts.
  
  
  RESULTS
  Myocytes were exposed to either a maximally activating level of extracellular calcium at 37 degrees C or to 2 mmol/L calcium at 32 degrees C. There was no significant difference in the contraction amplitude between myocytes from failing and nonfailing hearts at 0.2 Hz. With increasing stimulation frequency, there was a reduction in contraction amplitude in cells from failing hearts relative to control hearts in both maximal calcium from 0.33 Hz (4.5% versus 6.6%) to 1.4 Hz (3.9% versus 8.8%) (ANCOVA, P < .001) and at 2 mmol/L calcium from 0.50 Hz (2.3% versus 3.5%) to 1.4 Hz (1.8% versus 3.9%) (ANCOVA, P < .001). The time to peak contraction and the times to 50% and 90% relaxation were prolonged in myocytes from failing hearts at stimulation rate of 0.2 Hz (P < .01), but only the time to 50% relaxation was prolonged at 1.0 Hz (P < .05).
  
  
  CONCLUSIONS
  Reduced contraction, slowed relaxation, and impaired frequency response occurring at the level of the individual ventricular myocyte can be demonstrated in human heart failure. This demonstrates that disruption of myocyte function can contribute to both the systolic and the diastolic abnormalities that occur in the failing human heart.
authors.affiliation: Department of Cardiac Medicine, National Heart and Lung Institute, London, UK.
authors.forename: C H
authors.initials: CH
authors.lastname: Davies
authors.forename: K
authors.initials: K
authors.lastname: Davia
authors.forename: J G
authors.initials: JG
authors.lastname: Bennett
authors.forename: J R
authors.initials: JR
authors.lastname: Pepper
authors.forename: P A
authors.initials: PA
authors.lastname: Poole-Wilson
authors.forename: S E
authors.initials: SE
authors.lastname: Harding
mesh_terms: D000328:Adult; D002118:Calcium / Q000494:pharmacology*; D002478:Cells, Cultured; D003327:Coronary Disease / Q000503:physiopathology; D005260:Female; D006333:Heart Failure / Q000503:physiopathology*; D006352:Heart Ventricles / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects
chemical_list: D002118:Calcium